Technology | February 09, 2010

Popular Statin Cleared to Help Reduce Stroke, Heart Attack, Revascularization

February 9, 2010 – The FDA approved CRESTOR (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction and arterial revascularization procedures in individuals without clinically evident coronary heart disease. The new indication is for patients with an increased risk of cardiovascular disease (CVD) based on age, high-sensitivity C-reactive, and the presence of at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease.

The FDA approval was based on data from the landmark JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) study, which evaluated the impact of CRESTOR 20 mg on reducing major cardiovascular (CV) events in a previously unstudied population. In JUPITER, CRESTOR significantly reduced the relative risk of heart attack by 54 percent, stroke by 48 percent and arterial revascularization by 46 percent vs. placebo.

JUPITER included 17,802 men (age 50 and older) and women (age 60 and older) who had no clinically evident cardiovascular disease. The study population had an estimated baseline coronary heart disease risk of 11.6 percent over 10 years based on the Framingham risk criteria and included a high percentage of patients with additional risk factors such as hypertension (58 percent), low HDL-C levels (23 percent), cigarette smoking (16 percent), or a family history of premature CHD (12 percent).

Results from JUPITER were originally presented in November 2008 at the American Heart Association’s Annual Scientific Sessions, and published in the New England Journal of Medicine.

CRESTOR is already indicated in the United States as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, non-HDL-C, and TG levels and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. CRESTOR is also indicated as an adjunct to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower total-C and LDL-C to target levels.

For more information: www.astrazeneca.com

Related Content

Technology | Radial Access| February 17, 2017
Medtronic plc announced that its coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line...
Sponsored Content | Videos | Inventory Management| February 17, 2017
The supplies you use in your cath lab are complex and very valuable.
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Cardinal Health survey, hospital staff, supply chain management, quality of care
News | Inventory Management| February 15, 2017
Better hospital supply chain management leads to better quality of care and supports patient safety, according to a new...
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Biotronik, PRO-Kinetic Energy cobalt chromium coronary stent system, FDA approval
Technology | Stents Bare Metal| February 15, 2017
The PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from Biotronik has gained U.S. Food and Drug...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
HeartFlow FFRct Analysis, NICE guidance, U.K., United Kingdom, guidelines, stable chest pain
News | CT Angiography (CTA)| February 14, 2017
The National Institute for Health and Care Excellence (NICE) in the United Kingdom recently issued guidance for use of...
News | Hypertension| February 13, 2017
Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s...
 Intra-atrial shunt device (IASD) to lower left atrial pressure by creating a small left atrial to right atrial shunt.  Abraham said these devices are in early stage development with small studies to show proof of concept and demonstrate safety.

The Corvia Intra-atrial shunt device (IASD) lowers left atrial pressure by creating a small left atrial to right atrial shunt. Preliminary clinical studies have shown promise for these types of devices to improve HFpEF patient outcomes.

Feature | Heart Failure| February 10, 2017 | Dave Fornell
In the past few years there have been a number of device therapies developed to treat heart failure (HF).
Overlay Init